DOCSLIB.ORG

Gilead Sciences Appoints Flavius Martin, MD As Executive Vice President, Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gilead Sciences Appoints Flavius Martin, MD As Executive Vice President, Research Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research March 26, 2021 – William (“Bill”) Lee, PhD to Retire After 30 Years at Gilead – FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 26, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Flavius Martin, MD will join the company as Executive Vice President, Research, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day . Dr. Martin will assume responsibility for Gilead’s research organization effective April 12, 2021. Bill Lee, PhD, is retiring from Gilead after three decades. Dr. Martin brings to his new role significant experience overseeing industry-leading research, with particular expertise in oncology and inflammation. He joins Gilead from Amgen, Inc., where he most recently served as Vice President, Research Biology, leading discovery for Oncology, Inflammation and Cardiometabolic Research. He was also the site-head for Amgen South San Francisco. Prior to Amgen, Dr. Martin worked as a scientist and leader at Genentech, Inc. “Flavius brings decades of experience in early drug discovery research and identification of promising therapeutic candidates,” said Mr. O’Day. “He has deep scientific expertise across therapeutic areas and has led the creation of high-quality portfolios in prior roles. I am delighted to welcome him to Gilead as we continue to expand and diversify our portfolio of new medicines.” Dr. Martin received his MD at the University of Medicine and Pharmacy Timisoara, Romania. He completed his postdoctoral training at the University of Alabama at Birmingham in the Division of Developmental and Clinical Immunology. He has published numerous papers on the role of immune cells in driving inflammatory diseases and cancer, and holds a number of patents related to his discoveries. “Gilead has outstanding research and clinical development programs across Virology, Immunology and Oncology, and I am tremendously excited to be joining an organization with such a deep and talented scientific core,” commented Dr. Martin. “Throughout my career, I have been focused on translating scientific discoveries into the development of potential new therapies with the goal of helping people with unmet medical needs. I look forward to pursuing this mission together with the talented team at Gilead.” Dr. Lee joined Gilead in 1991. Over his 30-year career with the company, he has overseen research programs across multiple therapeutic areas and has led the advancement of numerous therapies from early-stage research into clinical development. His expertise contributed to the discovery of medicines and the identification of external partnerships. “Bill’s contributions over three decades have allowed Gilead to bring important new medicines to patients around the world,” said Mr. O’Day. “I am grateful to Bill for the high bar he has set for Gilead’s research organization and the commitment he demonstrated pursuing scientific advancements that transformed care for people with serious diseases.” About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. View source version on businesswire.com: https://www.businesswire.com/news/home/20210326005064/en/ Jacquie Ross, Investors (650) 358-1054 Marni Kottle, Media (650) 522-5388 Source: Gilead Sciences, Inc..
Load more

Recommended publications
  • J. SCOTT MCBRIDE PARTNER ━ 54 West Hubbard Street, Chicago, IL 60654 | 312.494.4436 | [email protected]
    J. SCOTT MCBRIDE PARTNER ━ 54 West Hubbard Street, Chicago, IL 60654 | 312.494.4436 | [email protected] EDUCATION & HONORS The University of Chicago Law School, 2002, J.D., with High Honors Order of the Coif 1st Place, Hinton Moot Court The University of Chicago Law Review Northwestern University, 1994, M.S. Ed., Earned Illinois Secondary Teaching Certificate for Chemistry, Physics and German Dartmouth College, 1992, A.B., summa cum laude, High Honors in Chemistry Phi Beta Kappa Rufus Choate Scholar German Academic Exchange Service Scholarship Chandler T. White Chemistry Research Prize CLERKSHIPS Honorable Richard D. Cudahy, United States Court of Appeals for the Seventh Circuit, 2002-2003 ADMISSIONS Illinois INTELLECTUAL PROPERTY LITIGATION ViiV Healthcare v. Gilead Sciences (D. Del.) Lead trial counsel for Gilead in patent infringement case related to Gilead's Biktarvy® HIV treatment. Case pending. www.bartlit-beck.com CHICAGO 312.494.4400 DENVER 303.592.3100 J. SCOTT MCBRIDE Adverio Pharma GmbH v. Alembic Pharmaceuticals, Ltd. et al. (D. Del.) Lead trial counsel for Adverio and Bayer in Hatch-Waxman litigation relating to Bayer's Adempas® (riociguat) treatment for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Gilead Sciences v. Mylan Pharmaceuticals (D. Del.) Lead trial counsel for Gilead in Hatch-Waxman litigation relating to Gilead's Tybost® (cobicistat) product. Case settled favorably. UroPep v. Eli Lilly (E.D. Tex.) Lead trial counsel (with my partners John Hughes) for UroPep in patent infringement action related to Lilly's Cialis product. Trial verdict for UroPep with damages of $20 million; affirmed on appeal. Regents of the Univ.
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • AMGEN INC. V. SANOFI
    Case: 20-1074 Document: 159 Page: 1 Filed: 06/21/2021 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ AMGEN INC., AMGEN MANUFACTURING, LIMITED, AMGEN USA, INC., Plaintiffs-Appellants v. SANOFI, AVENTISUB LLC, FKA AVENTIS PHARMACEUTICALS INC., REGENERON PHARMACEUTICALS INC., SANOFI-AVENTIS U.S. LLC, Defendants-Appellees ______________________ 2020-1074 ______________________ Appeal from the United States District Court for the District of Delaware in Nos. 1:14-cv-01317-RGA, 1:14-cv- 01349-RGA, 1:14-cv-01393-RGA, 1:14-cv-01414-RGA, Judge Richard G. Andrews. ______________________ JEFFREY A. LAMKEN, MoloLamken LLP, Washington, DC, filed a petition for rehearing en banc for plaintiffs-ap- pellants. Also represented by SARAH JUSTINE NEWMAN, MICHAEL GREGORY PATTILLO, JR.; SARA MARGOLIS, New York, NY; EMILY JOHNSON, ERICA S. OLSON, STEVEN TANG, STUART WATT, WENDY A. WHITEFORD, Amgen Inc., Thou- sand Oaks, CA; KEITH HUMMEL, Cravath Swaine & Moore LLP, New York, NY; WILLIAM G. GAEDE, III, McDermott Case: 20-1074 Document: 159 Page: 2 Filed: 06/21/2021 2 AMGEN INC. v. SANOFI Will & Emery LLP, Menlo Park, CA; CHRISTOPHER B. MEAD, Schertler Onorato Mead & Sears LLP, Washington, DC; JAMES L. HIGGINS, MELANIE K. SHARP, Young, Cona- way, Stargatt & Taylor, LLP, Wilmington, DE. Plaintiff- appellant Amgen Inc. also represented by SARAH CHAPIN COLUMBIA, McDermott, Will & Emery LLP, Boston, MA; LAUREN MARTIN, Quinn Emanuel Urquhart & Sullivan LLP, Boston, MA. MATTHEW WOLF, Arnold & Porter Kaye Scholer LLP, Washington, DC, filed a response for defendants-appellees. Also represented by VICTORIA REINES; DAVID K. BARR, DANIEL REISNER, New York, NY; DEBORAH E.
    [Show full text]
  • 1976 3M Medical Solutions Division 2019 Electrocore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2019 electroCore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc. 2010 Endo Pharmaceuticals 2018 Organogenesis 2013 AbbVie Inc. 2017 Exelixis 2004 Otsuka America Pharmaceutical, Inc. 2021 Adaptive Biotechnologies 2016 Express Scripts Federal Pharmacy 2018 Pacira BioSciences, Inc. 2017 ACADIA Pharmaceuticals, Inc. 2010 Federal Practitioner 2018 Paratek Pharmaceuticals 2020 AcelRx Pharmaceuticals, Inc. 2018 Foundation Medicine, Inc. 1990 Pfizer Pharmaceuticals 2020 Acorda Therapeutics 2021 Frontier Technology Inc. (FTI) 2017 Pharmacyclics, LLC 2019 Aimmune 2020 Fresenius Medical Care North America 2020 RedHill BioPharma 2003 Alcon Laboratories, Inc. 1989 Genentech Inc. 2019 Red One Medical 2019 Alexion Pharmaceuticals, Inc. 2006 Gilead Sciences 2020 Regeneron 2017 Alkermes, Inc. 1983 GLAXOSMITHKLINE 2009 Regenesis Biomedical, Inc. 2019 Alnylam Pharmaceuticals 2013 Golden State Medical Supply, Inc. 2011 Remund Group, LLC 2019 Altarum Institute 2020 GRAIL 2018 Rigel Pharmaceuticals 2020 Amarin Corporation 2019 Greenwich Biosciences 2000 Sanofi 1994 AmerisourceBergen 2013 Gulf Coast Pharmaceuticals Plus, LLC 2020 Seattle Genetics 1992 Amgen 2008 Heritage Health Solutions, Inc. 2004 Siemens Medical Solutions 2020 Amneal Pharmaceutical 2017 Hill-Rom Company 2019 SK Life Science, Inc. 2019 Aptive Resources LLC 2020 Immunomedics 2002 Smith & Nephew, Inc. 2020 The Arbinger Institute 2019 ImmunoVation, LLC 2019 Sobi Inc. 2011 Arbor Pharmaceuticals, LLC 2019 Incyte Corporation 2013 Stryker Orthopaedics 2010 Argentum Medical, LLC 2019 Indivior 2018 Sun Pharmaceutical 2019 ASM Research, LLC 2015 Intercept Pharmaceuticals 1999 Sunovion Pharmaceuticals, Inc. 1986 Astellas Pharma US, Inc. 2019 Ipsen Biopharmaceuticals, Inc. 2016 Taiho Oncology, Inc. 1995 AstraZeneca 2018 IT Cadre 2015 Takeda Oncology 2020 Baudax Bio, Inc.
    [Show full text]
  • COVID-19 Pharmacotherapy MATTHEW F
    COVID-19 Pharmacotherapy MATTHEW F. DERAEDT, PHARM.D., B.C.P.S. ANMC EMERGENCY DEPARTMENT PHARMACIST LT, USPHS Disclosure •No conflicts of interest to disclose •Recommendations to follow primarily from Alaska Native Medical Center’s Policy and Procedures •Clinical questions regarding specific patients should be deferred to ANMC Infectious Disease Department •Rapidly evolving FDA EUA and approved indications Objectives •Understanding inclusion and exclusion criteria for COVID-19 pharmacotherapies •Mechanism of action (MOA), pharmacokinetics, and pharmacodynamics for various therapies •Monitoring parameters for pharmacotherapies •Regulatory requirements for emergency use authorization therapies Remdesivir (Veklury®) •Adenosine nucleotide analog prodrug that is metabolized intracellularly to a nucleoside monophosphate intermediate •The nucleoside monophosphate is phosphorylated to active compound nucleoside triphosphate metabolite •The remdesivir- triphosphate (RDV TP) competes with ATP for incorporation into nascent RNA chains by SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) •Inhibits RNA chain termination Adamsick ML, et al. JASN. 2020:31(7):1384 - 1386 Remdesivir [package insert]. Foster City, CA. Gilead Sciences Inc. 2020. Road To Approval •FDA released on Emergency Use Authorization (EUA) May 1, 2020 •FDA approval on October 22, 2020 for adult patients and pediatric patients 12 years of age or older weighing at least 88 lbs (40kg) for the treatment of hospitalized COVID-19 patients •No longer need to follow EUA requirements for the approved patient population •Three Clinical Trials 1. NIAID ACTT-1: Mild/moderate and Severe COVID-19 2. GS-US-540-5774: Moderate COVID-19 3. GS-US-540-5773: Severe COVID-19 Remdesivir [package insert]. Foster City, CA. Gilead Sciences Inc. 2020. Spinner CD, et al.
    [Show full text]
  • Mark One) (X) QUARTERLY REPORT PURSUANT to SECTION 13 OR 15(D) of the SECURITIES EXCHANGE ACT of 1934
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 1997 ------------------ OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 0-19034 ------- REGENERON PHARMACEUTICALS, INC. ------------------------------------------------------ (Exact name of registrant as specified in its charter) New York 13-3444607 ------------------------------- ------------------------------------ (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 ---------------------------------------- ---------- (Address of principal executive offices) (Zip code) (914) 347-7000 ---------------------------------------------------- (Registrant's telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No ----- ----- Indicate the number of shares outstanding of each of the issuer's classes of common stock as of November 3, 1997: Class of Common Stock
    [Show full text]
  • COVID-19 Therapies and Vaccine Landscape
    editorial COVID-19 therapies and vaccine landscape Within a few weeks of the novel coronavirus genome sequence being published, numerous therapies and vaccines have entered clinical trials with a few showing great promise in alleviating symptoms and accelerating recovery. n late 2019, patients presenting with viral next-generation vaccine development can be pneumonia were reported in Wuhan, expedited by utilizing sequence information IChina, and a novel coronavirus was alone rather than relying on in vitro cultures quickly identified as the causative pathogen of live viruses. Nucleic acid-based vaccines that leads to severe acute respiratory that use this next-generation approach have syndrome (SARS-CoV-2) or COVID- been the frontrunners for COVID-19. One 19. The widely reported unpredictability such example is an mRNA vaccine (mRNA- of the disease means that some infected 1273 — encoding for the virus spike protein individuals are asymptomatic, some have used by viruses to latch onto human host mild flu-like symptoms, whereas other cells) developed by Moderna Therapeutics unfortunate individuals suffer from major and the National Institutes of Health has complications. The lower respiratory tract is already shown promising signs and is the main target for severe symptoms, where Credit: Andrey Deryabin/Alamy Stock Photo currently finalizing preparations for phase high virus shedding has been observed. The III clinical trials7. Another frontrunner body defends itself by an elevated immune in phase IIB/III clinical trials, ChAdOX1 response
    [Show full text]
  • Pharma: Strategic Realignment for a 112/113 Better Future Prism / 2 / 2020
    Pharma: Strategic realignment for a 112/113 better future Prism / 2 / 2020 Pharma: Strategic realignment for a better future ... and how the industry will be forced to overcome its hesitation to innovate in operations Ben van der Schaaf, Aurelien Guichard The life sciences sector faces significant impact from Amid the search for COVID-19 – and although the race for treatments and vaccines effective COVID-19 treatments and vaccines, is dominating the headlines, the effect on the industry will the pandemic will have not solely be positive. long-term side effects for the global pharmaceutical In the short term, some companies industry. As our article explains, companies are laying people off and reducing will need to focus on operations, whereas others are change in three areas reallocating resources to focus on (portfolio reprioritization, COVID-19, or even ramping up accelerated R&D and technology efforts in other areas. Stock-market transformation) if they performance has been as diverse are to position (Figure 1). themselves successfully for the future. Organizations need to consider major strategic questions now, to ensure their success in the longer term. The industry is clearly in the middle of the efforts to combat COVID-19: - More than 20 companies are trying to find a treatment with either new or approved drugs1. - More than 15 companies globally are mobilizing resources to develop new vaccines2. - Globally, by the end of May, more than 1,300 clinical trials related to COVID-19 were recruiting patients3. 1. Marketwatch.com, 6 May 2020 2. Drugtargetreview.com, 9 April 2020 3. clintrials.gov, 31 May 2020 Pharma: Strategic realignment for a 114/115 better future Prism / 2 / 2020 2.
    [Show full text]
  • Sixth Circuit I.O.P
    RECOMMENDED FOR FULL-TEXT PUBLICATION Pursuant to Sixth Circuit I.O.P. 32.1(b) File Name: 15a0199p.06 UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT _________________ DINO RIKOS et al., ┐ Plaintiffs-Appellees, │ │ │ No. 14-4088 v. │ > │ THE PROCTER & GAMBLE COMPANY, │ Defendant-Appellant. │ ┘ Appeal from the United States District Court for the Southern District of Ohio at Cincinnati. No. 1:11-cv-00226—Timothy S. Black, District Judge. Argued: June 16, 2015 Decided and Filed: August 20, 2015 Before: MOORE and COOK, Circuit Judges; COHN, District Judge.* _________________ COUNSEL ARGUED: Brian J. Murray, JONES DAY, Chicago, Illinois, for Appellant. Timothy G. Blood, BLOOD HURST & O’REARDON, San Diego, California, for Appellees. ON BRIEF: Brian J. Murray, JONES DAY, Chicago, Illinois, D. Jeffrey Ireland, FARUKI IRELAND & COX P.L.L., Cincinnati, Ohio, Joanne Lichtman, BAKER & HOSTETLER LLP, Cleveland, Ohio, Chad A. Readler, Rachel Bloomekatz, JONES DAY, Columbus, Ohio, for Appellant. Timothy G. Blood, Leslie E. Hurst, Thomas J. O’Reardon II, BLOOD HURST & O’REARDON, San Diego, California, for Appellees. MOORE, J., delivered the opinion of the court in which COHN, D.J., joined. COHN, D.J. (pg. 37), delivered a separate concurring opinion. COOK, J. (pp. 38–40), delivered a separate dissenting opinion. *The Honorable Avern Cohn, United States District Judge for the Eastern District of Michigan, sitting by designation. 1 No. 14-4088 Rikos et al. v. The Procter & Gamble Co. Page 2 _________________ OPINION _________________ KAREN NELSON MOORE, Circuit Judge. The named plaintiffs-appellees (“Plaintiffs”) are three individuals who purchased Align, Procter & Gamble’s (“P&G”) probiotic nutritional supplement, and found that the product did not work as advertised—that is, it did not promote their digestive health.
    [Show full text]
  • In the United States District Court for the District of Delaware
    Case 1:20-cv-00561-UNA Document 1 Filed 04/24/20 Page 1 of 27 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AMGEN INC. and AMGEN MANUFACTURING, LIMITED, C.A. No. ________ Plaintiffs, v. HOSPIRA, INC. and PFIZER INC., DEMAND FOR JURY TRIAL Defendants. COMPLAINT Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited (collectively, “Plaintiffs”), by and through their undersigned attorneys, for their Complaint against Defendants Hospira, Inc. and Pfizer Inc. (collectively, “Defendants”) hereby allege as follows: THE PARTIES 1. Amgen Inc. is a corporation existing under the laws of the State of Delaware, with its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320. Amgen Inc. discovers, develops, manufactures, and sells innovative therapeutic products based on advances in molecular biology, recombinant DNA technology, and chemistry. Founded in 1980, Amgen Inc. is a pioneer in the development of biological human therapeutics. Today, Amgen Inc. is one of the largest biotechnology companies in the world, fueled in part by the success of NEUPOGEN® (filgrastim). 2. Amgen Manufacturing, Limited (“AML”) is a corporation existing under the laws of Bermuda with its principal place of business in Juncos, Puerto Rico. AML manufactures and sells biologic medicines for treating particular diseases in humans. AML is a wholly-owned subsidiary of Amgen Inc. Case 1:20-cv-00561-UNA Document 1 Filed 04/24/20 Page 2 of 27 PageID #: 2 3. On information and belief, Hospira, Inc. (“Hospira”) is a corporation existing under the laws of the State of Delaware, with its principal place of business at 275 North Field Drive, Lake Forest, Illinois 60045.
    [Show full text]
  • Sued Manufacturers of Antiretroviral HIV/AIDS Treatment Drugs
    For Immediate Release: February 25, 2021 Contact: Matt Baca -- (505) 270-7148 Attorney General Balderas Files Suit Against Manufacturers of Antiretroviral HIV/AIDS Treatment Drugs Santa Fe, NM---Attorney General Balderas today filed a lawsuit in the First Judicial District Court of New Mexico against Gilead Sciences, Inc., Bristol-Myers Squibb, Gilead Sciences, LLC, and Teva Pharmaceuticals USA, Inc., for violating the New Mexico Antitrust Act and New Mexico Unfair Practices Act. The lawsuit stems from the development, marketing, and manufacturing of several antiretroviral medications used in the prevention and treatment of Human Immunodeficiency Virus (“HIV”) – a disease which, if left untreated, destroys the immune system and leads to Acquired Immunodeficiency Syndrome (“AIDS”). The antiretroviral medications at issue include VIREAD®, TRUVADA®, ATRIPLA®, VEMLIDY®, and DESCOVY®. “Putting profits over the critical needs of New Mexican patients and risking their health and safety is unacceptable,” said Attorney General Balderas. “My office will hold anyone accountable who takes advantage of or harms our families.” The lawsuit alleges that the defendants engaged in coordinated schemes and anti- competitive agreements to suppress the entry of cheaper generic versions of each drug into the market, and to delay the development of safer, more effective treatment drugs in order to maintain a stranglehold on the market for antiretroviral treatment. The defendants’ schemes resulted in vastly inflated prices for these lifesaving drugs, and hundreds of millions of dollars in anticompetitive profits to the defendants. These profits came at the expense of government payors like the State of New Mexico, and patients living with HIV. A copy of the complaint filed in New Mexico Court is attached.
    [Show full text]
  • Surprises in the Industry's Most Profitable Companies
    June 20, 2008 Surprises in the industry's most profitable companies Evaluate Vantage An analysis of the industry’s most profitable companies last year throws up some surprising names within the top ten – ViroPharma tops the league table with a net income margin of 47%, generating all its profits from sales of anti-bacterial agent Vancocin. Interestingly, two Indian generic firms feature, Sun Pharmaceutical Industries and Glenmark Pharmaceuticals, perhaps dispelling the notion that margins from selling generics are always low. Of the big pharma players, only those US groups with mature product portfolios, namely Pfizer, Merck & Co and Amgen, make it into the list. However, looking at forecast margins for the current year, the table below also reveals that Merck & Co drops out of the top ten, impacted by significantly lower sales from its cholesterol franchise. Alcon replaces Merck, suggesting one good reason why Novartis recently decided to fork out $11bn to acquire a 25% stake in the eye-care company. This analysis from EvaluatePharma is based on dividing normalised net income (excluding exceptional items) by the total revenues, to generate a net margin percentage. It only includes companies that have reported two consecutive years of profit, with incomes in excess of $50m in both 2007 and 2008. 2007 - top 10 companies Net Margin Net Income - Normalised ($m) Total Revenues ($m) 2007 2006 2007 2007 ViroPharma 47% 66 95 204 Sun Pharmaceutical Industries 44% 159 371 837 Gilead Sciences 38% 1,204 1,615 4,230 Biovail 35% 428 293 843 OSI Pharmaceuticals
    [Show full text]